Currently, the anti-PD-1 agent pembrolizumab is approved for use as first- and second-line therapy in patients with advanced NSCLC whose tumors express PD-L1 in immunohistochemical analysis1,6. Here, PDCD1 is linked to non-small cell lung carcinoma.